Cargando…

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

INTRODUCTION: Subcutaneous versions of different oncology therapies have been available for patients for a few years, yet patient-relevant and hospital benefits have not been assessed in real life. METHODS: In order to analyze the impact of subcutaneous administrations for rituximab or trastuzumab i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ponzetti, Clemente, Canciani, Monica, Farina, Massimo, Era, Sara, Walzer, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883807/ https://www.ncbi.nlm.nih.gov/pubmed/27284260 http://dx.doi.org/10.2147/CEOR.S97319

Ejemplares similares

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach
por: Ponzetti, Clemente, et al.
Publicado: (2016)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2017)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
por: Theodore-Oklota, Christina, et al.
Publicado: (2016)

Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
por: Abad-Sazatornil, María Reyes, et al.
Publicado: (2021)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
por: Papadmitriou, K., et al.
Publicado: (2015)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home
por: Tjalma, WAA, et al.
Publicado: (2017)

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study
por: García‐Muñoz, Ricardo, et al.
Publicado: (2019)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
por: Kassem, Loay, et al.
Publicado: (2019)

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
por: Rojas, Luis, et al.
Publicado: (2020)

Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
por: Mao, Cheng-Ping, et al.
Publicado: (2013)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
por: Lopez-Vivanco, G., et al.
Publicado: (2017)

Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research
por: Lin, Hsiang-Wen, et al.
Publicado: (2023)

Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE
por: Falanga, Marina, et al.
Publicado: (2018)

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
por: De Cock, Erwin, et al.
Publicado: (2016)

Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
por: Harvey, Michael J., et al.
Publicado: (2022)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
por: Jackisch, Christian, et al.
Publicado: (2022)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
por: Van den Nest, Miriam, et al.
Publicado: (2019)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
por: Galecio, Juan Sebastián, et al.
Publicado: (2020)

Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration
por: Fadel, Charbel, et al.
Publicado: (2022)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
por: Ahmed, A. Razzaque, et al.
Publicado: (2018)

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
por: McCloskey, Conor, et al.
Publicado: (2022)

Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
por: Pimentel, Franklin Fernandes, et al.
Publicado: (2018)

Rituximab-Induced Interstitial Lung Disease: A Stitch in Time Saved Nine
por: Tej, Sai, et al.
Publicado: (2022)

Greening the office: Saving resources, saving money, and educating our patients
por: Blum, Stacy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mma0nrc602v7ll1d1h9au6unrk